LONN Share Price Performance
CHF 0
0.00 (0.00%)
Price CHF 0
Fair ValueCHF 663.52
Share Pricen/a
Narrative Update • Jun 06
Lonza Group AG Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 44 Fair Values set on narratives written by author
LONN Community Narratives
AN
Fair Value
·Fair Value CHF 663.52 26.3% undervalued intrinsic discount
Vacaville And Visp Facilities Will Secure Future Biologics Demand
0users have liked this narrative
0users have commented on this narrative
30users have followed this narrative
Vacaville And Visp Facilities Will Secure Future Biologics Demand
Lonza is betting big on new manufacturing sites and automation to meet growing demand from drugmakers that want to outsource complex biologics and next‑generation therapies. The upside comes with real execution risk—if these expansions ramp slowly or competition heats up, profits and cash flow could disappoint.Read more
AN
CHF 663.52
26.3% undervalued intrinsic discount
Fair Value
Revenue
11.08% p.a.
Profit Margin
18.86%
Future PE
31.26x
Price in 2029
CHF 762.88
Trending Discussion
Recently Updated Narratives
AN
LONN: Recovery In Life Science Tools Demand Will Drive Future Upside
Fair Value: CHF 663.52 26.3% undervalued intrinsic discount
30 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Lonza Group AG Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Jul 22, 2026
- 13.01
- 35.97%
- 13.92%
- 54.3%
About LONN
- Founded
- 1897
- Employees
- 20000
- CEO
- WebsiteView website
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
